AIDX · XBRL financial data
20/20 Biolabs financial statements, every quarter
The same tables from 3 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (AIDX's year ends in late December)
| In thousands of dollars | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|
| Revenue | year only | 353 | 731 |
| Cost of revenue | year only | 290 | 426 |
| Gross profit | year only | 63 | 305 |
| Research and development | year only | 153 | 258 |
| Selling, general and administrative | year only | 1,353 | 1,291 |
| Total operating expenses | year only | 1,506 | 1,549 |
| Operating income (loss) | year only | (1,443) | (1,244) |
| Interest income | year only | 7 | 14 |
| Interest expense | year only | 267 | 272 |
| Other income (expense) | year only | — | (0) |
| Net income (loss) | year only | (2,175) | (1,506) |
| Earnings per share, basic USD per share | — | (0.28) | (0.26) |
| Earnings per share, diluted USD per share | — | (0.28) | (0.26) |
| Weighted average shares, basic thousands of shares | — | 7,657 | 10,791 |
| Weighted average shares, diluted thousands of shares | — | 7,657 | 10,791 |
Balance sheet
CSVFiscal quarters (AIDX's year ends in late December)
| In thousands of dollars | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|
| Cash and cash equivalents | 1,026 | 4,219 | 4,546 |
| Accounts receivable | 200 | 201 | 291 |
| Inventory | 116 | 105 | 111 |
| Prepaid and other current assets | 129 | 175 | 127 |
| Total current assets | 1,471 | 4,700 | 5,076 |
| Property and equipment, net | 57 | 45 | 34 |
| Right-of-use asset | 605 | 563 | 519 |
| Total assets | 4,137 | 5,803 | 6,123 |
| Accounts payable | 869 | 980 | 1,027 |
| Accrued liabilities | 786 | 598 | 743 |
| Total current liabilities | 2,463 | 2,580 | 2,551 |
| Lease liability, non-current | 489 | 429 | 380 |
| Total liabilities | 4,157 | 3,046 | 2,964 |
| Accumulated deficit | (33,247) | (35,422) | (36,928) |
| Total stockholders' equity | (19) | 2,553 | 1,621 |
| Total liabilities and equity | 4,137 | 5,803 | 6,123 |
| Common shares outstanding (cover page) thousands of shares | 10,443 | 10,612 | 12,770 |
Cash flows
CSVFiscal quarters (AIDX's year ends in late December)
| In thousands of dollars | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|
| Net income (loss) | year only | (2,175) | (1,506) |
| Stock-based compensation | year only | 128 | 371* |
| Depreciation and amortization | year only | 12 | 12* |
| Net cash from operating activities | year only | (1,289) | (605)* |
| Net cash from investing activities | — | (5) | (8)* |
| Net cash from financing activities | year only | 4,487 | 940* |
| Net change in cash | year only | 3,193 | 327* |
Compare with peers
SIC 8734 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 8734 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| 20/20 Biolabs | 4,546 | 731 | (605)* | 12.8M | 7.5 quarters | 10-QJun 30, 2026 |
| bioAffinity Technologies | 2,430 | 1,511 | (3,201)* | 8.1M | 0.8 quarters | 10-QJun 30, 2026 |
| Absci | 107,865 | not reported | (27,564)* | 171.6M | 7.3 quarters | 10-QJun 30, 2026 |
| OneMedNet | 358 | 292 | (1,875)* | 59.3M | 0.2 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.